(RS)-α-methyl-4-carboxyphenylglycine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (RS)-α-methyl-4-carboxyphenylglycine
• 英文别名: α-methyl-4-carboxyphenylglycine；N-(4-carboxyphenyl)alanine；4-(1-Carboxyethylamino)benzoic acid
• 化学式: C₁₀H₁₁NO₄
• 分子量: 209.202
• InChiKey: RZAPRBYXMPEHOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  DL-丙氨酸 、 对氯苯甲酸 在 di-tert-butyl{2′-isopropoxy-[1,1′-binaphthalen]-2-yl}phosphane 、 potassium hydroxide 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 叔丁醇 为溶剂， 反应 20.0h， 以88%的产率得到(RS)-α-methyl-4-carboxyphenylglycine
  参考文献：
  名称：

  氨基酸（酯）与芳基溴化物和氯化物的钯催化偶联反应

  摘要：

  庞大且富电子的MOP型配体和Pd（dba）2组合对氨基酸与非活性芳基卤化物的偶合反应显示出N-芳基氨基酸的高效反应。在催化条件下，不仅α-氨基酸，而且β-，γ-和δ-氨基酸都以中等至高收率与芳基氯偶合。在光学纯的β-氨基酸作为底物的情况下，保留了偶联产物的光学纯度。

  DOI：

  10.1016/j.tet.2011.09.109

文献信息

• Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
  申请人：——

  公开号：US20030055085A1

  公开（公告）日：2003-03-20

  The present invention provides compounds and pharmaceutical compositions that act as antagonists at metabotropic glutamate receptors, and that are useful for treating neurological diseases and disorders. Methods of preparing the compounds also are disclosed.

  本发明提供了作为代谢型谷氨酸受体拮抗剂的化合物和药物组合物，用于治疗神经系统疾病和障碍。还公开了制备这些化合物的方法。
• Pyridine and pyrimidine derivatives as mGIuR2 antagonists
  申请人：McArthur Silvia Gatti

  公开号：US20070232583A1

  公开（公告）日：2007-10-04

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, pharmaceutical compositions containing them, and their use for treating CNS disorders: wherein A, B, X, Y, R 1 , R 2 , R 3 and R 4 are as defined in the description and claims.

  本发明涉及式(I)的化合物，其制造方法，含有它们的药物组合物，以及它们用于治疗中枢神经系统疾病的用途：其中A、B、X、Y、R1、R2、R3和R4如描述和权利要求中所定义。
• Inhibitors of Histone Deacetylase
  申请人：Grimm Jonathan B.

  公开号：US20090069250A1

  公开（公告）日：2009-03-12

  The present invention relates to a novel class of compounds. These compounds can inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and sale dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.

  本发明涉及一类新型化合物。这些化合物可以抑制组蛋白去乙酰化酶，并适用于在选择性诱导终末分化、阻止肿瘤细胞生长和/或凋亡的过程中使用，从而抑制这些细胞的增殖。因此，本发明的化合物在治疗具有肿瘤特征的患者方面是有用的，这些肿瘤由肿瘤细胞增殖引起。本发明的化合物还可能在预防和治疗TRX介导的疾病方面有用，如自身免疫、过敏和炎症性疾病，以及预防和/或治疗中枢神经系统（CNS）疾病，如神经退行性疾病。本发明还提供包含本发明化合物的药物组合物，以及这些药物组合物的销售用剂量方案，易于遵循，并在体内产生这些化合物的治疗有效量。
• PAK INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE DISORDERS
  申请人：AFRAXIS, INC.

  公开号：US20130116263A1

  公开（公告）日：2013-05-09

  Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of cell proliferative disorders and/or CNS disorders.

  本文提供了PAK抑制剂以及利用PAK抑制剂治疗细胞增殖性疾病和/或中枢神经系统疾病的方法。
• DIHYDRO-BENZO[B][1,4]DIAZEPIN-2-ONE SULFONAMIDE DERIVATIVES
  申请人：Gatti McArthur Silvia

  公开号：US20080261957A1

  公开（公告）日：2008-10-23

  The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) wherein R 1 , R 2 , R 3 and R 4 are defined as in the specification.

  本发明涉及式(I)的化合物，其制备方法，它们用于制备用于治疗中枢神经系统疾病的药物以及含有它们的药物组合物。式(I)的化合物由通用式(I)表示，其中R1、R2、R3和R4如规范中定义。